Please login to the form below
dermatitis
This page shows the latest dermatitis news and features for those working in and with pharma, biotech and healthcare.
AbbVie’s upadacitinib aces phase III trial
even climb as high as $5bn at peak if it also shows its worth in follow-up indications like psoriatic arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis and atopic dermatitis.
Latest news
-
NICE rejects Sanofi’s Dupixent for atopic dermatitis at first call
A proposal by Sanofi to discount the cost to the NHS of its Dupixent drug for atopic dermatitis has not been enough to sway NICE, which has said it cannot back ... It’s accepting comments on its initial decision until 24 April. Dupixent (dupilumab) was
-
Dermira craters as acne drug fails late-stage test
Also in its pipeline is an injectable drug for atopic dermatitis - I L-13 inhibitor lebrikizumab - which was developed by Roche and licensed to Dermira in a deal valued at up ... That programme is in mid-stage clinical testing. Even if it successfully
-
AbbVie reports more solid data for would-be psoriasis blockbuster
The latest data, updating earlier results reported last year, showed that upadacitinib was able to significantly reduce the itch associated with atopic dermatitis after just one week and improved the extent ... AbbVie now says it plans to begin pivotal
-
Takeda bags EU approval for Adcetris in lymphoma
CTCL is the most common type of cutaneous lymphoma and typically presents with red, scaly patches or thickened plaques of skin that often looks like eczema or chronic dermatitis.
-
Sanofi and Regeneron ramp up immuno-oncology collaboration
Finally, there will also be more money to accelerate and expand the development of the firms’IL-33 antibody REGN3500, with studies expected to be conducted in atopic dermatitis, asthma and
More from news
Approximately 7 fully matching, plus 44 partially matching documents found.
Latest Intelligence
-
Pharma deals continue to slide
Phase II MAb to block IL-13 for treatment of atopic dermatitis.
-
Deal Watch September 2016
as well as other autoimmune disorders plus VTP-38543 for atopic dermatitis.
-
Deal Watch July 2016
AstraZeneca is developing tralokinumab for severe asthma, where it is in phase III development, and has recently completed a phase IIb study in patients with atopic dermatitis.
-
Allergies and asthma
Early prevention is recommended. Allergic diseases (eg food allergies, rhinitis, asthma, atopic dermatitis) usually start in childhood but can develop at any age. ... of the hypo-allergenic milk formula on cow's milk allergy and atopic dermatitis (AD).
-
Deal Watch May 2016
Paying a 55% premium at $99.25 per share, the acquisition brings crisaborole, a topical PDE4 inhibitor for mild to moderate atopic dermatitis (eczema) with estimated peak sales of $2bn.
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
Latest appointments
-
Dr Desiree Luthman joins Verona Pharma
atopic dermatitis in the US.
-
Ziarco appoints Mike Grey to board of directors
Concerning his appointment, Grey said: “ I am delighted to join Ziarco's board, as the company has a strong leadership team and promising lead compounds for the treatment of atopic dermatitis
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Research Partnership launches new patient Living with Atopic Dermatitis (US) 2017 report
Research Partnership launches new patient Living with Atopic Dermatitis (US) 2017 report. ... Living with Atopic Dermatitis (AD) is a study conducted amongst 100 adults and 50 caregivers in the US.
-
Research Partnership has published a new patient Living with Atopic Dermatitis (US) report
Research Partnership has published a new patient Living with Atopic Dermatitis (US) report. ... An attitudinal segmentation is included to help identify the unique groups of patients Atopic Dermatitis.
-
Bringing sufferers out of the shadows – Reducing the emotional impact of living with Atopic Dermatitis
Bringing sufferers out of the shadows – Reducing the emotional impact of living with Atopic Dermatitis. ... Atopic dermatitis (AD) or eczema is a chronic inflammatory skin disease, which, although not as debilitating as other chronic conditions, can
-
Research Partnership
We are one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical industry, we provide custom solutions and strategic recommendations that go beyond research,
More from PMHub
Approximately 3 fully matching, plus 1 partially matching documents found.
Featured jobs
- Senior / Principal Regulatory Writer – Home Working - UK or US
-
HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS
- Head of Operations/ BUD, Healthcare PR, London – Excellent leade...
-
Excellent Package
- Editorial Team Leader or Scientific Director
-
£50, 000 - £55, 000 benefits
-
Account Manager, Healthcare PR
-
£40, 000 – £42, 000 great benefits and bonuses
- Account Manager – Med Comms – London
-
Salary TBC
- Senior Medical Writer, Medical Communications, Relocate to Cardi...
-
Excellent Salary
- Senior Account Manager / Account Director
-
Great salary and bebefits
-
Scientific Director
-
Great salary and bebefits
- Editor – Medical Education Agency – Bucks
-
Salary TBC
-
Senior Medical Writer
-
Great salary and bebefits
- FREELANCE Account Manager – Creative Healthcare Advertising – Lo...
-
SUPERB DAY RATES AVAILABLE
-
Senior Programme Executive
-
Salary TBC
-
Senior Medical Writer
-
Great salary and benefits
- Editor > Senior Editor – Medical Education – London
-
Very competitive with excellent benefits
- Principal Medical Writer, Medical Communications, Relocate to Ca...
-
Excellent Salary
- Senior Account Manager – Med Comms – Kent
-
Salary TBC
- FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...
-
EXCELLENT DAY RATES AVAILABLE
Subscribe to our email news alerts
PMHub
Four Health Media
Four Health Media creates world class integrated media solutions with global reach, deep insight, innovative methods and a highly personal...
Latest intelligence
- The Holy Grail of HCP Access
- This is the data you need to gain access....
- No incentive for a cure
- The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
- Why heading online for scientific meetings can yield greater HCP engagement
- Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
Quick links
Infographics
